Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD – Get Free Report) was the target of a significant decline in short interest in October. As of October 15th, there was short interest totalling 26,400 shares, a decline of 22.8% from the September 30th total of 34,200 shares. Currently, 1.8% of the company’s shares are short sold. Based on an average daily trading volume, of 2,600,000 shares, the days-to-cover ratio is presently 0.0 days.
Galmed Pharmaceuticals Stock Down 2.5 %
GLMD stock opened at $3.93 on Monday. The stock has a market capitalization of $2.52 million, a price-to-earnings ratio of -0.23 and a beta of 0.73. Galmed Pharmaceuticals has a 52-week low of $2.73 and a 52-week high of $23.80. The stock’s fifty day simple moving average is $4.81 and its 200-day simple moving average is $4.36.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last released its earnings results on Wednesday, August 28th. The biopharmaceutical company reported $2.16 earnings per share for the quarter.
Wall Street Analysts Forecast Growth
View Our Latest Stock Analysis on GLMD
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
See Also
- Five stocks we like better than Galmed Pharmaceuticals
- What Are Trending Stocks? Trending Stocks Explained
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- Using the MarketBeat Stock Split Calculator
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What Is WallStreetBets and What Stocks Are They Targeting?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.